[Enzyme immunoassay for pregnancy-specific beta 1-glycoprotein (SP-1) in patients with testicular tumors].
The use of a two-side-binding-enzyme-immunoassay for pregnancy-specific beta 1-glycoprotein (SP-1) in tumours of the testicles is described. The lower limit of evidence is with 4 ng/ml near to the physiological region. In 17 of 41 non-seminomatous germinal tumours of the testicles (41%) initially increased SP-1-serum concentrations were present, the other measuring values correlated with the course of the disease. In all tumours of the testicles with initially increased SP-1-titres the use of the SP-1-test gives a further possibility of the regulation of therapy and control of the course.
D000293:Adolescent; D002369:Castration; D002822:Choriocarcinoma / Q000175:diagnosis; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000175:diagnosis; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D011257:Pregnancy Proteins / Q000378:metabolism*; D011268:Pregnancy-Specific beta 1-Glycoproteins / Q000378:metabolism*; D013724:Teratoma / Q000175:diagnosis; D013736:Testicular Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery
D011257:Pregnancy Proteins; D011268:Pregnancy-Specific beta 1-Glycoproteins
Enzymimmunoassay für schwangerschaftsspezifisches beta 1-Glycoprotein (SP-1) bei Patienten mit Hodentumoren.